89 research outputs found
The acute and postprandial effects of sugar moiety on vascular and metabolic health outcomes in adolescents
This is the author accepted manuscript. The final version is available from Canadian Science Publishing via the DOI in this recordThis study explored the cardiometabolic responses to sugar moieties acutely, and following a
subsequent mixed meal tolerance test (MMTT). Twenty-one healthy adolescents (N=10
female, 14.3±0.4 years) completed three experimental and one control condition, in a
counterbalanced order. These consisted of different drinks to compare the effect of 300 mL of
water (control), or 300 mL of water mixed with 60 g of glucose, fructose or sucrose, on vascular
function (flow-mediated dilation; FMD, microvascular reactivity (total hyperaemic response;
TRH); and cerebrovascular reactivity; CVR), and blood samples for [uric acid], [glucose],
[triglycerides] and [lactate]. FMD increased 1 hour after glucose and sucrose (P<0.001,
ESâ„0.92) but was unchanged following fructose and water (P>0.19, ES>0.09). CVR and TRH
were unchanged 1 hour following all conditions (P>0.57, ES>0.02). Following the MMTT, FMD
was impaired in all conditions (P0.40) with no differences between conditions
(P>0.13, ES<0.39). Microvascular TRH was increased in all conditions (P=0.001, ES=0.88),
and CVR was preserved in all conditions post MMTT (P=0.87, ES=0.02). Blood [uric acid] was
elevated following fructose consumption and the MMTT (P0.40). Consumption of a
sugar sweetened beverage did not result in vascular dysfunction in healthy adolescents,
however the vascular and metabolic responses were dependent on sugar moiety
CONCEPTT: Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy Trial: A multi-center, multi-national, randomized controlled trial - Study protocol.
BACKGROUND: Women with type 1 diabetes strive for optimal glycemic control before and during pregnancy to avoid adverse obstetric and perinatal outcomes. For most women, optimal glycemic control is challenging to achieve and maintain. The aim of this study is to determine whether the use of real-time continuous glucose monitoring (RT-CGM) will improve glycemic control in women with type 1 diabetes who are pregnant or planning pregnancy. METHODS/DESIGN: A multi-center, open label, randomized, controlled trial of women with type 1 diabetes who are either planning pregnancy with an HbA1c of 7.0 % to â€10.0 % (53 to â€â86 mmol/mol) or are in early pregnancy (<13 weeks 6 days) with an HbA1c of 6.5 % to â€10.0 % (48 to â€â86 mmol/mol). Participants will be randomized to either RT-CGM alongside conventional intermittent home glucose monitoring (HGM), or HGM alone. Eligible women will wear a CGM which does not display the glucose result for 6 days during the run-in phase. To be eligible for randomization, a minimum of 4 HGM measurements per day and a minimum of 96 hours total with 24 hours overnight (11 pm-7 am) of CGM glucose values are required. Those meeting these criteria are randomized to RT- CGM or HGM. A total of 324 women will be recruited (110 planning pregnancy, 214 pregnant). This takes into account 15 and 20 % attrition rates for the planning pregnancy and pregnant cohorts and will detect a clinically relevant 0.5 % difference between groups at 90 % power with 5 % significance. Randomization will stratify for type of insulin treatment (pump or multiple daily injections) and baseline HbA1c. Analyses will be performed according to intention to treat. The primary outcome is the change in glycemic control as measured by HbA1c from baseline to 24 weeks or conception in women planning pregnancy, and from baseline to 34 weeks gestation during pregnancy. Secondary outcomes include maternal hypoglycemia, CGM time in, above and below target (3.5-7.8 mmol/l), glucose variability measures, maternal and neonatal outcomes. DISCUSSION: This will be the first international multicenter randomized controlled trial to evaluate the impact of RT- CGM before and during pregnancy in women with type 1 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01788527 Registration Date: December 19, 2012
Pregnancy and neonatal outcomes of COVID-19: The PAN-COVID study
Objective
To assess perinatal outcomes for pregnancies affected by suspected or confirmed SARS-CoV-2 infection.
Methods
Prospective, web-based registry. Pregnant women were invited to participate if they had suspected or confirmed SARS-CoV-2 infection between 1st January 2020 and 31st March 2021 to assess the impact of infection on maternal and perinatal outcomes including miscarriage, stillbirth, fetal growth restriction, pre-term birth and transmission to the infant.
Results
Between April 2020 and March 2021, the study recruited 8239 participants who had suspected or confirmed SARs-CoV-2 infection episodes in pregnancy between January 2020 and March 2021.
Maternal death affected 14/8197 (0.2%) participants, 176/8187 (2.2%) of participants required ventilatory support. Pre-eclampsia affected 389/8189 (4.8%) participants, eclampsia was reported in 40/ 8024 (0.5%) of all participants.
Stillbirth affected 35/8187 (0.4 %) participants. In participants delivering within 2 weeks of delivery 21/2686 (0.8 %) were affected by stillbirth compared with 8/4596 (0.2 %) delivering â„ 2 weeks after infection (95 % CI 0.3â1.0). SGA affected 744/7696 (9.3 %) of livebirths, FGR affected 360/8175 (4.4 %) of all pregnancies.
Pre-term birth occurred in 922/8066 (11.5%), the majority of these were indicated pre-term births, 220/7987 (2.8%) participants experienced spontaneous pre-term births. Early neonatal deaths affected 11/8050 livebirths. Of all neonates, 80/7993 (1.0%) tested positive for SARS-CoV-2.
Conclusions
Infection was associated with indicated pre-term birth, most commonly for fetal compromise. The overall proportions of women affected by SGA and FGR were not higher than expected, however there was the proportion affected by stillbirth in participants delivering within 2 weeks of infection was significantly higher than those delivering â„ 2 weeks after infection. We suggest that cliniciansâ threshold for delivery should be low if there are concerns with fetal movements or fetal heart rate monitoring in the time around infection
Processing LHC data in the UK
The Large Hadron Collider (LHC) is one of the greatest scientific endeavours to date. The construction of the collider itself and the experiments that collect data from it represent a huge investment, both financially and in terms of human effort, in our hope to understand the way the Universe works at a deeper level. Yet the volumes of data produced are so large that they cannot be analysed at any single computing centre. Instead, the experiments have all adopted distributed computing models based on the LHC Computing Grid. Without the correct functioning of this grid infrastructure the experiments would not be able to understand the data that they have collected. Within the UK, the Grid infrastructure needed by the experiments is provided by the GridPP project. We report on the operations, performance and contributions made to the experiments by the GridPP project during the years of 2010 and 2011-the first two significant years of the running of the LHC
GridPP:the UK grid for particle physics
The start-up of the Large Hadron Collider (LHC) at CERN, Geneva, presents a huge challenge in processing and analysing the vast amounts of scientific data that will be produced. The architecture of the worldwide grid that will handle 15 PB of particle physics data annually from this machine is based on a hierarchical tiered structure. We describe the development of the UK component (GridPP) of this grid from a prototype system to a full exploitation grid for real data analysis. This includes the physical infrastructure, the deployment of middleware, operational experience and the initial exploitation by the major LHC experiments
DEVELOPMENT STUDIES FOR THE OPAL ENDCAP ELECTROMAGNETIC CALORIMETER USING VACUUM PHOTO TRIODE INSTRUMENTED LEAD GLASS
Evidence for an endogenous circannual component in the control of the annual gonadal cycle in spotted munia
- âŠ